Actualités et vidéos - MENDUS AB [CBOE]

Mendus is a clinical-stage immuno-oncology company focused on the development of off-the-shelf therapies for haematological ......

Press Release Stockholm, Sweden, March 19, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will present the progress of its NK cell program at the 9th Annual Innate Killer Cell Summit, a leading conference for NK cell-based therapies. Mendus Director of Research Satwinder Kaur Singh, PhD will be expert speaker at the 9 th Annual Innate Killer Summit held March 18-20 in San Diego, CA, USA. The Innate...

Press Release Stockholm, Sweden, March 15, 2024 Mendus AB (“Mendus” or the “Company”) has received written declarations of intent whereby the Company’s major shareholders, holding approximately 65.8 percent of shares in the Company, declare their intention to exercise warrants of series TO3 (the “Warrants”) to subscribe for newly issued shares corresponding to their holdings of Warrants during the subscription period 15-29 March 2024 at the subscription price of 0.48 SEK per share....

Press Release Stockholm, Sweden, March 15, 2024 On June 8, 2023, Mendus AB (publ) (“Mendus” or the “Company”), (NASDAQ Stockholm: IMMU), announced that the Board of Directors had resolved on a capital raise of approximately SEK 317 million (the “Transaction”), comprised of a directed issue of shares and warrants to Flerie Invest AB of approximately SEK 90 million (the “Directed Issue”), in combination with a fully secured rights issue of units of approximately SEK 227 million...

Press Release Stockholm, Sweden, March 12, 2024 ADVANCE II Phase 2 trial data provide basis for late-stage development of lead product vididencel in acute myeloid leukemia Registration trial preparations are ongoing, following positive initial FDA feedback on main questions related to late-stage clinical development and large-scale manufacturing Manufacturing alliance with NorthX Biologics on track, with production facility installed and tech transfer process for large-scale GMP manufacturing of...

Press release Stockholm, Sweden, February 27, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming industry conferences: 10th annual IO360° Summit New York, USA, February 27-29, 2024 CEO Erik Manting will participate in the 10th annual IO360° Summit, a conference dedicated to reporting on the latest advancements and data in Immuno-Oncology....

Press Release Stockholm, Sweden, February 23, 2024 Mendus AB (“Mendus” publ; IMMU.ST), will hold an in-person and live-streamed business update event in Stockholm on March 12, 15:00-17:00 CET to discuss the company’s latest pipeline advancements. Mendus has recently presented positive Phase 2 data with vididencel in acute myeloid leukemia (AML), an aggressive blood-borne tumor associated with high relapse rates, at the ASH 2023 conference. Vididencel addresses the need for safe and...

Press Release Stockholm, Sweden, February 14, 2024 Positive ADVANCE II data at ASH caps strong 2023 The fourth quarter of 2023 closes a crucial year for Mendus and delivered additional milestones to further strengthen the development of our lead product vididencel as a novel maintenance treatment for acute myeloid leukemia (AML). Mendus is at an exciting point in its journey, supported by continued positive clinical data confirming the potential of vididencel to significantly improve...

In this video, Soo Romanoff, healthcare managing director of Edison Group, interviews Erik Manting, CEO of Mendus. Mendus is a ......

Mendus AB (“Mendus” publ; IMMU.ST), will publish its year-end report for 2023 on Wednesday 14 February 2024 at 08:00 CET. The company will hold a conference call and an online presentation on the same day at 10:00 CET. The call will be hosted by CEO Erik Manting. The presentation will be in English and followed by a question-and-answer session. Listen to the presentation webcast: https://ir.financialhearings.com/mendus-q4-2023 Please send any questions ahead of the presentation to...

Press release Stockholm, Sweden, January 8, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences: 42 nd Annual J.P. Morgan Healthcare Conference San Francisco, USA, January 8-11, 2024 Mendus management team will be in San Francisco for business and investor meetings during the J.P, Morgan conference...

Press Release Stockholm, Sweden, December 22, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, announced an update on the status and outlook of its clinical pipeline programs. Mendus reports completion of the long-term follow up of the MERECA trial studying the intratumoral immune primer ilixadencel in metastatic renal cell carcinoma (mRCC). The long-term follow up data confirmed the observations previously reported,...

Press Release Stockholm, Sweden, December 13, 2023 At the extraordinary general meeting (the “ EGM ”) of Mendus AB (publ), reg. no. 556629-1786, (the “ Company ”), on 13 December 2023 the EGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the meeting and the complete proposals for resolutions, which have previously been published and are available on the Company’s website,...

Press Release Stockholm, Sweden, December 11, 2023 As of November 24, 2023, median relapse-free survival (mRFS) stood at 30.4 months Median overall survival (mOS) was not reached, with the majority of patients (14/20) still alive Reduction in measurable residual disease (MRD) and induction of immune responses correlate with RFS and OS benefit, confirming vididencel mechanism of action Virtual KOL event with principal investigator to discuss new ASH data on Thursday, December 14, 2023, at 9.00 am...

Press Release Stockholm, Sweden, December 6, 2023 CADENCE Phase 2 trial will evaluate vididencel in combination with oral azacitidine Randomized controlled trial in 40 patients, with potential to extend up to 140 patients Collaboration with ALLG to significantly strengthen Mendus clinical trial network Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the company has entered into a collaboration with...

Press Release Stockholm, Sweden, December 5, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced it will present the development of a robust, scaled up industrial process for vididencel supply at the Cell & Gene Therapy Manufacturing & Commercialization Conference held Dec 4-6 in Dublin. Mendus Chief Technology Officer Leopold Bertea will chair the Cell Therapy Manufacturing & Analytics session on Dec 5...

Press Release Stockholm, Sweden, December 4, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced it will host a virtual KOL Event on December 14, 2023 at 9:00 AM ET, featuring Dr. Arjan van de Loosdrecht, Professor of Hematology at Amsterdam UMC and Principal Investigator of the ADVANCE II trial, who will discuss the current treatment landscape for patients with Acute Myeloid Leukemia (AML) and the...

Mendus is a clinical-stage immunoncology company developing its lead candidate, vididencel, a cell-based vaccine, as a cancer ......

Press Release Stockholm, Sweden, November 17, 2023 Mendus AB (publ: IMMU.ST) announced today that the members of the Nomination Committee have been appointed in accordance with the principles for appointment of the Nomination Committee, adopted by the Annual General Meeting of May 4, 2021. The members of Mendus’ Nomination Committee shall be appointed by the four largest shareholders, as of August 31, 2023, who wish to exercise their right to appoint a representative. If four shareholders have...

Press Release Stockholm, Sweden, November 13, 2023 The shareholders of Mendus AB (publ) (the “ Company ”), reg. no 556629-1786, are hereby invited to the Extraordinary General Meeting (“ EGM ”) on Wednesday, 13 December 2023, at 16:00, at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm. Registration for the meeting will commence at 15:30. NOTIFICATION Shareholders who wish to attend the meeting must: (i) both be recorded in the share register maintained by Euroclear Sweden AB...